Pelacarsen lowered Lp(a) without reducing cardiovascular events in Lp(a)HORIZON. A breakdown of the findings and their limits.
On November 7, 2026, Cleveland Clinic published its account of the Phase 3 Lp(a)HORIZON trial of pelacarsen. Cleveland Clinic cardiologist Steven Nissen chaired the study, which tested an experimental treatment targeting lipoprotein(a), or Lp(a).
The Phase 3 trial found that pelacarsen substantially lowered Lp(a) without reducing the primary cardiovascular outcome. According to Cleveland Clinic’s report, that outcome occurred in 12.3% of participants assigned to pelacarsen and 12.1% assigned to placebo over a median 4.7 years. For healthy aging, the central finding is the gap between changing a biological target and demonstrating a meaningful health benefit. A strong biomarker response was not matched by fewer of the serious cardiovascular events the trial was designed to prevent.
Evidence type: Human research. This was a Phase 3 clinical trial in people with elevated Lp(a) and established cardiovascular disease, not a cell or animal study.
The trial enrolled 8,350 people across 797 sites in 42 countries. Cleveland Clinic reported that 8,322 participants were included in the efficacy analysis. Participants received a monthly injection of pelacarsen or placebo, alongside guideline-based secondary-prevention therapy as indicated.
Secondary prevention means the study concerned people who already had cardiovascular disease. The question was whether adding pelacarsen to their existing care would reduce further events, rather than whether lowering Lp(a) could prevent a first event.
The primary outcome combined cardiovascular death with nonfatal heart attack, nonfatal ischemic stroke, or urgent coronary revascularization requiring hospitalization. This placed the central test on clinical events rather than a laboratory measurement alone.
Healio reported no statistically significant differences in the individual outcomes either. That includes cardiovascular death and heart attack, as well as stroke and urgent revascularization. The neutral overall result therefore was not accompanied by a reported significant benefit in one of those individual components.
Pelacarsen is an antisense oligonucleotide designed to lower Lp(a). Cleveland Clinic’s report described a substantial effect on that target: at 12 months, median Lp(a) levels were 64.4 nmol/L in the pelacarsen group and 233.4 nmol/L in the placebo group.
The reported treatment difference was 77.7%. This is a comparison between the trial groups, not a statement that every participant experienced the same change. Keeping the comparison attached to its measurement time also matters: these were the reported Lp(a) results at 12 months.
This separates two questions that are often blurred in emerging-therapy coverage. Did the intervention change its intended biological target? Did that change improve the clinical outcome being tested? Lp(a)HORIZON produced different answers to those questions.
For longevity research, a useful habit is to distinguish intermediate biological responses from patient outcomes. A biomarker result can show that an intervention affected its target. Treating that result as proof of clinical benefit skips the question that an outcomes trial is designed to answer.
Nissen called the findings “disappointing and unexpected,” according to Cleveland Clinic. He also described the extensive analyses as essentially neutral. That reaction reflects the contrast at the heart of the study: substantial target lowering alongside an unchanged primary event outcome.
Novartis funded the trial, according to Cleveland Clinic. That is relevant context for interpreting the report, not a reason by itself to dismiss the findings.
Start by identifying the measured endpoint when assessing an emerging therapy claim. A report of lower Lp(a) answers a different question from a report of fewer heart attacks or strokes. This is the same evidence distinction behind assessing emerging therapies by clinical results, rather than by the appeal of their mechanisms.
A useful claim check is to ask which group was studied, what the comparator was, and whether the headline describes a blood measurement or an event outcome. In this case, the comparator was placebo on top of indicated secondary-prevention care. That context is more informative than the size of the biomarker change alone.
Leslie Cho, the trial’s first author and principal investigator, said Lp(a) remains a causal risk factor and emphasized LDL lowering. Her interpretation of Lp(a) biology should sit alongside the neutral clinical result, not replace it. Personal decisions about lipid results or cardiovascular medicines belong with a qualified clinician who can interpret existing disease and current care.
Reuters reported that Amgen’s olpasiran and Eli Lilly’s lepodisiran remain under investigation. Cleveland Clinic also listed muvalaplin among other Lp(a)-lowering therapies whose outcome-trial results remain to be seen. Their status as research programs is distinct from evidence that they prevent clinical events.
Bloomberg reported that Novartis would discontinue pelacarsen development for atherosclerotic cardiovascular disease while continuing a study in calcific aortic valve stenosis. The continuing valve study addresses a separate question from preventing the cardiovascular events measured in Lp(a)HORIZON. These programs should be evaluated by the outcomes they actually test.
The next decisive step is cardiovascular-outcome evidence from other Lp(a)-lowering therapies, with each result judged against the drug tested and the population enrolled.
Judging pelacarsen by cardiovascular outcomes rather than target reduction requires an evidence standard that AgeAmaze makes easier to understand. Its coverage addresses overstated emerging-therapy claims for skeptical adults by explaining the biology and showing how a measured response differs from an established benefit.
Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.
Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.
read the Blog
